D.C. Circuit Holds 340B Program Does Not Prohibit Drug Manufacturers from Imposing Contract Pharmacy Restrictions jdsupra.com/legalnews/d-c-…

D.C. Circuit Becomes Second Federal Appeals Court to Allow Restrictions on 340B Contract Pharmacies jdsupra.com/legalnews/d-c-…

Women With Broken Paragard Copper IUDs May Qualify to File a Lawsuit jdsupra.com/legalnews/wome…

[Ongoing Program] SESSION 2: Do I Really Need A Privacy Officer, DPO or CISO? - July 18th, 1:00 pm - 1:45 pm CT jdsupra.com/legalnews/ongo…

[Ongoing Program] SESSION 3: Privacy Policy Pop Quiz – Are You Ready? - August 8th, 1:00 pm - 1:45 pm CT jdsupra.com/legalnews/ongo…

FDA signals potential shift toward interchangeability for all biosimilars jdsupra.com/legalnews/fda-…

Pay for Delay Is Sometimes Okay jdsupra.com/legalnews/pay-…

Achieving a High Performance, Diverse Accrual, Clinical Trial Program in an Academic Health System jdsupra.com/legalnews/achi…

Recent Regulatory Actions Against Unlicensed Pharmacy Benefit Managers in West Virginia jdsupra.com/legalnews/rece…

When a Gift Becomes a Kickback: Gifts from Florida Pharmacies to Long-Term Care Facilities jdsupra.com/legalnews/when…

Regeneron Files Second BPCIA Complaint Against Celltrion’s Proposed EYLEA® Biosimilar CT-P42 jdsupra.com/legalnews/rege…

The First Biosimilar Disputes at the Unified Patent Court (UPC) jdsupra.com/legalnews/the-…

The Appeals Review Panel’s In Re Xencor Decision: The USPTO Provides Its Position on Written Description and Means-Plus-Function Claims jdsupra.com/legalnews/the-…

[Ongoing Program] SESSION 1: 10 Things You Should Know About Privacy, Consent, and HIPAA - June 13th, 1:00 pm - 1:45 pm CT jdsupra.com/legalnews/ongo…

The EU AI Act: Key Takeaways for Life Sciences and Digital Health Companies jdsupra.com/legalnews/the-…

Supreme Court Holds Invalid Cholesterol Drug Patent That Covered Millions of Undisclosed Antibodies jdsupra.com/legalnews/supr…

FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf) and Samsung Bioepis’s Opuviz™ (aflibercept-yszy) jdsupra.com/legalnews/fda-…

Rethinking Interchangeability, Top Cases, and Battling Misinformation at FDLI’s Annual Conference jdsupra.com/legalnews/reth…

This Week in 340B: May 14 – May 20, 2024 jdsupra.com/legalnews/this…

FDA Approves Boehringer Ingelheim’s CYLTEZO® Biosimilar to Humira for Multiple Chronic Inflammatory Diseases jdsupra.com/legalnews/fda-…